ProShares - UltraShort Nasdaq Biotechnology (BIS) Fund Overview

ProShares - UltraShort Nasdaq Biotechnology (BIS) Financial Services Profile

ProShares UltraShort Nasdaq Biotechnology (BIS) offers a leveraged inverse exposure to the Nasdaq Biotechnology Index, targeting sophisticated investors seeking short-term hedging or speculative opportunities within the volatile biotech sector. It is important to understand the risks associated with leveraged and inverse ETFs before investing.

What Is the Investment Thesis for BIS?

BIS presents a tactical opportunity for investors with a short-term bearish outlook on the biotechnology sector. By providing -2x daily inverse exposure to the Nasdaq Biotechnology Index, BIS can generate gains when the index declines. However, the leveraged nature of the fund amplifies both gains and losses, making it a high-risk investment. Investors should closely monitor the biotech sector and be prepared to actively manage their positions. The fund's performance is highly sensitive to daily market movements, and its suitability for long-term investment is questionable due to the effects of compounding and volatility. A key consideration is the potential for rapid erosion of capital if the Nasdaq Biotechnology Index moves against the intended direction.

Based on FMP financials and quantitative analysis

BIS Key Highlights

BIS seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index.

• The fund is designed for short-term tactical positioning rather than long-term investment strategies.
• BIS is managed by ProShare Advisors LLC, a leading provider of alternative ETFs.
• The fund's beta is -1.47, indicating a high degree of inverse correlation with the Nasdaq Biotechnology Index.
• BIS does not offer a dividend yield, as its primary objective is to provide leveraged inverse exposure.

Who Are BIS's Competitors?

BIS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIS's Key Strengths?

Provides a convenient way to gain leveraged inverse exposure to the Nasdaq Biotechnology Index.

• Offers a tool for hedging against potential losses in biotech portfolios.
• Managed by ProShare Advisors LLC, a reputable provider of alternative ETFs.
• High inverse correlation with the Nasdaq Biotechnology Index, as indicated by its beta.

What Are BIS's Weaknesses?

Leveraged nature amplifies both gains and losses, making it a high-risk investment.

• Not suitable for long-term investment due to the effects of compounding and volatility.
• Performance is highly sensitive to daily market movements.
• Subject to management fees and expenses, which can reduce returns.

What Are the Key Risks for BIS?

The leveraged nature of BIS amplifies both gains and losses, making it a high-risk investment.

• The fund is not suitable for long-term investment due to the effects of compounding and volatility.
• Unexpected positive developments in the biotechnology sector could lead to losses.
• Changes in regulations governing leveraged and inverse ETFs could impact its operations.
• Competition from other similar products could reduce its market share.

What Are BIS's Competitive Advantages?

• Brand recognition and reputation of ProShares as a leading provider of alternative ETFs.
• Established track record of providing leveraged and inverse exposure to various indices.
• Expertise in managing complex financial instruments and derivatives.
• First-mover advantage in offering a leveraged inverse ETF focused on the Nasdaq Biotechnology Index.

What Does BIS Do?

ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund (ETF) managed by ProShare Advisors LLC. It was created to provide investors with a way to achieve daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index. This index comprises a selection of securities listed on the NASDAQ that are classified as biotechnology companies, making BIS a specialized tool for those with a view on the short-term direction of the biotech market. The fund is not designed for long-term investing and is best suited for sophisticated investors who understand the risks associated with leveraged and inverse ETFs. These types of funds can experience significant volatility and may not perform as expected if held for longer than a single day due to the effects of compounding. ProShares, as a company, is a leading provider of alternative ETFs, offering a range of products designed to help investors manage risk and enhance returns. Their focus is on providing tools that allow investors to express specific market views, whether bullish, bearish, or neutral.

What Products and Services Does BIS Offer?

• Provides leveraged inverse exposure to the Nasdaq Biotechnology Index.
• Offers a tool for investors to profit from declines in the biotechnology sector.
• Allows investors to hedge against potential losses in their biotech portfolios.
• Seeks daily investment results that are two times the inverse of the index's performance.
• Provides short-term tactical investment opportunities.
• Offers a way to express a bearish view on the biotechnology market.

How Does BIS Make Money?

• Generates revenue through management fees charged on the assets under management (AUM).
• Aims to track the daily performance of two times the inverse of the Nasdaq Biotechnology Index.
• Utilizes derivatives and other financial instruments to achieve its investment objective.
• Rebalances its portfolio daily to maintain the desired leverage ratio.

What Industry Does BIS Operate In?

The asset management industry is highly competitive, with numerous firms offering a wide range of investment products, including ETFs. Inverse and leveraged ETFs like BIS cater to a niche market of sophisticated investors seeking to express short-term market views. The biotechnology sector itself is characterized by high growth potential but also significant volatility due to factors such as clinical trial outcomes, regulatory approvals, and patent expirations. BIS provides a tool for investors to potentially profit from or hedge against this volatility. Competitors offer similar leveraged and inverse products across various sectors and asset classes.

Who Are BIS's Key Customers?

• Sophisticated investors seeking short-term tactical opportunities.
• Hedge funds and other institutional investors.
• Financial advisors managing client portfolios.
• Traders looking to profit from short-term declines in the biotechnology sector.

BIS Financials

BIS Latest News

No recent news available for BIS.

BIS Analyst Consensus

BIS MoonshotScore

BIS Financials Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources